tirzepatide and cancer risk New research suggests GLP 1 medications like semaglutide tirzepatide, widely used for weight loss and diabetes, may also lower the of several obesity related cancers, including colorectal, endometrial, and breast Preventing obesity-related cancer with the

[15] The complication rate is 2.4%

Final Clinical Perspective Dr

Specific triggers for medical consultation include achieving less than 5% body weight reduction after reaching the maintenance dose (for Wegovy, after 12 weeks at 2.4 mg as per FDA labeling), prolonged weight loss plateau despite adherence, or intolerable side effects preventing dose escalation to therapeutic levels

Vitamin C (in high doses) Role: Supports immunity and tissue repair

Sitagliptin has been associated with pancreatitis in postmarketing reports

They do not replace insulin While these medications lower blood sugar levels, they do not replace the need for insulin